1-5 of 5
Peggy A. Scherle
Close
Sort by
Journal Articles

PRT2527, a Novel Highly Selective Cyclin-Dependent Kinase 9 (CDK9) Inhibitor, Has Potent Antitumor Activity in Combination with BTK and BCL2 Inhibition in Various Lymphoid Malignancies

Norman Fultang, Ashley M Schwab, Sophia McAneny-Droz, Diane Heiser, Peggy A Scherle, Neha Bhagwat
Journal: Blood
Blood (2023) 142 (Supplement 1): 5783.
https://doi.org/10.1182/blood-2023-190093
Published: 2023
Journal Articles

Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia

Clinical Trials & Observations
Alireza Eghtedar, Srdan Verstovsek, Zeev Estrov, Jan Burger, Jorge Cortes, Carol Bivins, Stefan Faderl, Alessandra Ferrajoli, Gautam Borthakur, Solly George, Peggy A. Scherle, Robert C. Newton, Hagop M. Kantarjian, Farhad Ravandi
Journal: Blood
Blood (2012) 119 (20): 4614–4618.
https://doi.org/10.1182/blood-2011-12-400051
Published: 2012
Journal Articles

Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity

Xiangdong Liu, Niu Shin, Holly K. Koblish, Gengjie Yang, Qian Wang, Kathy Wang, Lynn Leffet, Michael J. Hansbury, Beth Thomas, Mark Rupar, Paul Waeltz, Kevin J. Bowman, Padmaja Polam, Richard B. Sparks, Eddy W. Yue, Yanlong Li, Richard Wynn, Jordan S. Fridman, Timothy C. Burn, Andrew P. Combs, Robert C. Newton, Peggy A. Scherle
Journal: Blood
Blood (2010) 115 (17): 3520–3530.
https://doi.org/10.1182/blood-2009-09-246124
Published: 2010
Journal Articles

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

Alfonso Quintás-Cardama, Kris Vaddi, Phillip Liu, Taghi Manshouri, Jun Li, Peggy A. Scherle, Eian Caulder, Xiaoming Wen, Yanlong Li, Paul Waeltz, Mark Rupar, Timothy Burn, Yvonne Lo, Jennifer Kelley, Maryanne Covington, Stacey Shepard, James D. Rodgers, Patrick Haley, Hagop Kantarjian, Jordan S. Fridman, Srdan Verstovsek
Journal: Blood
Blood (2010) 115 (15): 3109–3117.
https://doi.org/10.1182/blood-2009-04-214957
Published: 2010
Includes: Supplemental data
Journal Articles

The Clinical Phenotype of Myelofibrosis Encompasses a Chronic Inflammatory State That Is Favorably Altered by INCB018424, a Selective Inhibitor of JAK1/2

Ayalew Tefferi, MD, Hagop M Kantarjian, Animesh D. Pardanani, MBBS, PhD, Ruben A. Mesa, MD, FACP, Robert C Newton, PhD, Peggy A Scherle, PhD, Timothy Burn, PhD, Srdan Verstovsek
Journal: Blood
Blood (2008) 112 (11): 2804.
https://doi.org/10.1182/blood.V112.11.2804.2804
Published: 2008